Weight Loss Medications Show Promise in Reducing Mental Health Risks
A groundbreaking international study has found that weight loss jabs, commonly used for obesity and diabetes, may significantly help reduce symptoms of anxiety and depression. Researchers discovered that these medications are linked to a lower risk of mental health problems, with one type of drug showing a 44% decreased risk of worsening depression.
Key Findings from the Research
The study, published in The Lancet Psychiatry, analysed data from over 95,000 people in Sweden over a 13-year period. It included 22,480 individuals who used semaglutide, the active ingredient in popular weight loss drugs Ozempic and Wegovy. Compared to those who did not use the injections, semaglutide was associated with a 38% lower risk of worsening anxiety and a 44% lower risk of worsening depression. Additionally, it was linked to a reduced risk of substance abuse and binge drinking.
Another active ingredient, liraglutide, used in Saxenda, also showed a lower risk of worsening depression, though to a lesser extent. The researchers, from institutions including the University of Eastern Finland, Karolinska Institutet in Stockholm, and Griffith University in Australia, noted that these medications might serve as dually effective therapeutic options for anxiety and depression that co-occur with diabetes and obesity.
Mechanisms Behind the Effects
Research director Markku Lahteenvuo from the University of Eastern Finland explained that while the exact reasons are unclear, the association is strong. Potential factors include reduced alcohol consumption, improvements in body image due to weight loss, better glycaemic control in diabetes, and possible direct neurobiological mechanisms affecting the brain's reward system.
Context and Additional Research
Wegovy is regularly prescribed on the NHS for weight loss, while Ozempic is approved only for diabetes treatment. The study comes as separate research from Denmark examined accidental pregnancies among people taking GLP-1 receptor agonists, such as liraglutide and semaglutide, during early pregnancy. Analysing health records of 480,231 women, researchers found that exposure to these drugs was linked to an increased risk of pre-term birth when used for diabetes treatment, but not for weight management, suggesting underlying diabetes might be the causal factor.
This research highlights the potential mental health benefits of weight loss jabs, offering new insights into their broader therapeutic applications beyond physical health.
